Format

Send to

Choose Destination
Clin Infect Dis. 2016 Dec 15;63(12):1615-1618. Epub 2016 Sep 13.

Clinical Outcomes, Drug Toxicity, and Emergence of Ceftazidime-Avibactam Resistance Among Patients Treated for Carbapenem-Resistant Enterobacteriaceae Infections.

Author information

1
Department of Medicine.
2
Antibiotic Management Program.
3
XDR Pathogen Laboratory, University of Pittsburgh Medical Center.
4
Department of Pharmacy and Therapeutics, University of Pittsburgh.
5
Public Health Research Institute Tuberculosis Center, New Jersey Medical School, Rutgers University, Newark.
6
VA Pittsburgh Healthcare System, Pennsylvania.

Abstract

Thirty-seven carbapenem-resistant Enterobacteriaceae (CRE)-infected patients were treated with ceftazidime-avibactam. Clinical success and survival rates at 30 days were 59% (22/37) and 76% (28/37), respectively. In 23% (5/22) of clinical successes, CRE infections recurred within 90 days. Microbiologic failure rate was 27% (10/37). Ceftazidime-avibactam resistance was detected in 30% (3/10) of microbiologic failures.

KEYWORDS:

Klebsiella pneumoniae carbapenemase; carbapenem-resistant Enterobacteriaceae; ceftazidime-avibactam resistance

PMID:
27624958
PMCID:
PMC5146720
DOI:
10.1093/cid/ciw636
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Silverchair Information Systems Icon for PubMed Central
Loading ...
Support Center